Just in case anyone thinks the conjunctivitis study conclusions were a one off, then read this study from August 21
www.mdpi.com/1999-4915/13/8/1656/htm
Protective Effects of Astodrimer Sodium 1% Nasal Spray Formulation against SARS-CoV-2 Nasal Challenge in K18-hACE2 Mice
In it, Jeremy Paul et all conclude that:-
“The potential protective effects of astodrimer sodium 1% nasal spray warrant further investigation to help combat SARS-CoV-2 infection in humans.”
Not “immediate commercialisation”, but “further investigation ”.
How much more investigation? A month? A year?? Five years???
Just in case anyone thinks the conjunctivitis study conclusions...
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $41.73M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.0¢ | 9.8¢ | $6.156K | 62.05K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 22787 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 199768 | 2 |
View Market Depth
| Last trade - 16.10pm 02/10/2024 (20 minute delay) ? |
| SPL (ASX) Chart |